220 related articles for article (PubMed ID: 37403111)
1. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
Yao Y; Li B; Song R; Yang L; Zou B; Wang L
Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations.
Han J; Fu C; Li B
Radiat Oncol; 2021 Mar; 16(1):47. PubMed ID: 33663551
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
5. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
Xie Z; Liu J; Wu M; Wang X; Lu Y; Han C; Cong L; Li J; Meng X
J Clin Med; 2023 Jun; 12(11):. PubMed ID: 37298023
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
7. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.
Fang M; Wang L; Gu Q; Wu H; Du X; Lai X
Clin Exp Metastasis; 2023 Oct; 40(5):423-429. PubMed ID: 37584783
[TBL] [Abstract][Full Text] [Related]
10. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Wang BC; Fu C; Lin GH
Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study.
Xie J; Chen M; Han H; Xu K; Qiu G; Lin X; Song Y; Ye J; Lv T; Zhan P
Thorac Cancer; 2023 May; 14(15):1327-1338. PubMed ID: 37005095
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database.
Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP; Khuri FR; Curran WJ; Ramalingam SS; Behera M; Higgins KA
Clin Lung Cancer; 2019 Nov; 20(6):484-493.e6. PubMed ID: 31296433
[TBL] [Abstract][Full Text] [Related]
14. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung Cancer: Implications for Thoracic Radiotherapy.
Kim D; Kim HJ; Wu HG; Lee JH; Kim S; Kim TM; Kim JS; Kim BH
Cancer Res Treat; 2024 Apr; 56(2):430-441. PubMed ID: 37933113
[TBL] [Abstract][Full Text] [Related]
15. Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?
Luo J; Xu L; Zhao L; Cao Y; Pang Q; Wang J; Yuan Z; Wang P
Radiat Oncol; 2017 Feb; 12(1):42. PubMed ID: 28245874
[TBL] [Abstract][Full Text] [Related]
16. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
17. Impact of thoracic radiation therapy after chemotherapy on survival in extensive-stage small cell lung cancer: A propensity score-matched analysis.
Deng L; Zhou Z; Xiao Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Wang X; Zhang T; Wang W; Wang L
Thorac Cancer; 2019 Apr; 10(4):799-806. PubMed ID: 30779334
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST).
Patrice GI; Lester-Coll NH; Yu JB; Amdahl J; Delea TE; Patrice SJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):97-106. PubMed ID: 29029885
[TBL] [Abstract][Full Text] [Related]
19. Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
Longo V; Della Corte CM; Russo A; Spinnato F; Ambrosio F; Ronga R; Marchese A; Del Giudice T; Sergi C; Casaluce F; Gilli M; Montrone M; Gristina V; Sforza V; Reale ML; Di Liello R; Servetto A; Lipari H; Longhitano C; Vizzini L; Manzo A; Cristofano A; Paolelli L; Nardone A; De Summa S; Perrone A; Bisceglia C; Derosa C; Nardone V; Viscardi G; Galetta D; Vitiello F
Front Immunol; 2023; 14():1289434. PubMed ID: 38304255
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
